Turning Pennies into dollars: (OTC: NXPC), (OTCBB: XSNX), (OTC: CIRT), (OTCBB: GNTA), (OTCBB: ARSC)
Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559
For more info: http://nxpc.realpennies.com
NEXPLORE CORPORATION (OTC: NXPC)
NeXplore Technologies is developing a Web 2.0 search engine and an assortment of social networking portals and tools that will enable users to personalize their Web experience and tailor it to their unique needs, interests, and online pursuits. The Company's social computing platform, MyCircle.com, offers an enhanced, user-friendly graphical interface search engine, combined with innovative backend technology, which enables users to improve the way they connect with information and other people on the Worldwide Web. MyCircle's Web 2.0 interface provides users with an online tool for sharing their Blogs, Voice-Over IP, photos and documents, podcasts and videocasts, classified advertising, instant messages, SMS text messages, Chat and personal profiles.
NXPC News:
May 29 - NeXplore Signs LOI With LiveLoop Technologies
NeXplore Committed to Delivering Open, Interactive, Rich-Media Communication Capabilities for Social Computing Platform
NeXplore Corporation (OTC: NXPC) announced the company has signed a Letter of Intent with LiveLoop(TM) Technologies to explore incorporating a selection of LiveLoop's rich Internet applications (RIAs) into NeXplore Corporation's social computing platform.
Currently under development, NeXplore's social computing platform is a universally accessible, application-agnostic social computing platform providing users with a single, highly customizable interface for managing every facet of their online activity.
One of the more prominent LiveLoop RIAs NeXplore is evaluating for private label inclusion in its social computing platform offering is LiveLoop SocialCam Community(TM) - a dynamic video networking tool that provides face-to-face communication within a specially-designed community tailored to meet the goals, specifications and design of each member.
"In a market increasingly cluttered with walled-garden social networking sites, a key differentiator of the LiveLoop SocialCam Community is that users can participate in a SocialCam video chat or video conference from wherever they happen to be - MySpace, YouTube, Facebook, or most any social networking site. LiveLoop SocialCam works anywhere on the Web," said Tom Smith, president of LiveLoop Technologies. "NeXplore is on the cutting edge of the Web 2.0 world. The way people use the Internet to connect with information and each other is rapidly changing, and the NeXplore team gets it. We are very pleased to be working with NeXplore to discover how LiveLoop applications can further enhance and differentiate the company's portfolio of Web 2.0 tools and destinations."
"Being platform agnostic has been a guiding principle from day one with this project. Personalization and ease of use are also key elements," said Edward Mandel, chief executive officer of NeXplore Corporation. "LiveLoop interactive applications have the versatility to operate anywhere on the Web, which is certainly appealing."
Mandel added, "We are committed to providing our users with the most unique, very best possible online experience. We look forward to continued productive discussions with LiveLoop, and to doing all that we can to ensure consumers and marketers will be both pleased and amazed when we open our product for public beta."
ABOUT LIVELOOP TECHNOLOGIES
LiveLoop Technologies provides a platform and toolset that enable information and rich media content to be exchanged and communicated within an interactive environment on-web, direct-to-desktop, and direct to mobile. LiveLoop's highly intelligent and fully integrated suite of applications are ushering in a new age of convenient, connected communications. Stay in the LiveLoop. For more information visit www.livelooptech.com.
For more info: http://xsnx.realpennies.com
XSUNX INCORPORATED (OTCBB: XSNX)
Xsunx, Inc., a thin-film photovoltaic (TFPV) company, focuses on developing thin film photovoltaic (TFPV) amorphous silicon solar cell manufacturing processes to produce TFPV solar modules. Its product includes XsunX ASI-120 module, which is a 125 peak watt TFPV solar module utilizing glass substrates and a proprietary semiconductor manufacturing system. XsunX ASI-120 provides for a module delivering high power output, and size and framing that would allow for the use of various existing mounting systems. The target markets for the TFPV solar module include solar farms, government agencies, and utility companies, as well as power purchase agreements and large commercial installations worldwide. The company, formerly known as Sun River Mining, Inc., was incorporated in 1997 and changed its name to XsunX, Inc. in 2003. XsunX is headquartered in Aliso Viejo, California.
XSNX News:
May 29 - XsunX Announces Agreement with Newport Corporation as Its Laser Subsystems Supplier
Newport to Supply Key Laser Subsystems for the XsunX Solar Module Production Line
XsunX, Inc. (OTCBB: XSNX), a solar technology company engaged in the build-out of its multi-megawatt solar module manufacturing facility, announced that it has expanded its existing two-year relationship with Newport Corporation (NASD: NEWP) by selecting Newport as its preferred supplier for laser and motion subsystems for its integrated Thin Film Photovoltaic (PV) manufacturing line. These products are used to create monolithically interconnected cells on the solar panels and to laser scribe bar codes on the panels for quality control purposes.
Newport Corporation is a leading global supplier of advanced photonics technologies to customers in a wide range of industries. The company has developed innovative solutions for the automated manufacturing of solar cells that leverage its expertise in high-power lasers, precision positioning systems, vibration isolation and optical subsystems to enhance the speed and precision of the solar cell manufacturing process.
"We are pleased that XsunX has chosen us as their preferred supplier for lasers and precision motion subsystems, which play a key role in enabling high-precision, high-volume and low cost manufacture of thin film solar panels," stated Robert J. Phillippy, President and CEO of Newport. "We believe that XsunX's selection of Newport is a further validation of our ability to provide value-added solutions to our photovoltaic customers."
"Our relationship with Newport and their Spectra-Physics Lasers Division dates back to when they provided us with assistance in developing techniques for laser scribing of plastic substrates," stated Mr. Tom Djokovich, CEO of XsunX. "When XsunX migrated to designing a glass substrate module, Newport continued to provide support and problem solving expertise. Automating cell integration using lasers gives thin film an enormous economy of scale over crystalline. We are pleased to be working with a globally-recognized leader in the buildout of our multi-megawatt thin film photovoltaic solar manufacturing facility," concluded Djokovich.
For more info: http://cirt.realpennies.com
CARDIO INFRARED TECHNOLOGIES (OTC: CIRT)
Cardio Infrared Technologies, Inc is a technology and marketing company, which is focused on developing the revolutionary and evolutionary process of combining exercise equipment with medical benefits that go far beyond the normal benefits of standard exercise equipment. Cardio Infrared Technologies, Inc. is committed to continue to market this equipment to the exercise and medical markets and to aggressively expand the market to every country around the world. The equipment has already been featured on Good Morning America and The View. Cardio Infrared Technologies, Inc. also has an aggressive growth plan that includes acquisitions and development of innovate new equipment in the exercise and medical industries.
CIRT News:
May 29 - Cardio Infrared Announces Amazing News From Ongoing Clinical Trials, Names National Sales Director
Cardio Infrared Technologies, Inc. (OTC: CIRT), a leading Health and Wellness technology and marketing company, announced results of the mid-Clinical Trials and the promotion of Carol Anglin to the position of National sales director.
Wayne Bailey, President and CEO of Cardio Infrared Technologies, Inc. stated, ''The promotion of Carol Anglin to the position of National Sales Director for Cardio Infrared Technologies, Inc. will allow the continued aggressive pursuit of all sales leads that has and is leading to an ever expanding record of closed sales for Cardio-Cor unit. Carol joined the Cardio-Cor team in November 2006. Carol started working with Cardio Infrared Technologies, Inc. doing cold calls in the Utah market. Carol quickly completed sales of two units by the end of 2006. In 2007 she was doing cold calls on a nationwide basis developing sales leads and sales first on the East Coast and then on the West Coast. Carol has become a very valuable member of the Cardio-Cor sales and management team. The training she has received and the first hand observations of the results obtained by the public using the Cardio-Cor has given her a unique perspective that has added to the mounting sales momentum of Cardio Infrared Technologies, Inc. Carol was part of the team that attended the Anti-Aging show in December 2007 and was given the responsibility for the sales leads generated from that show. Carol has aggressively followed up on the leads generated by the shows, which has resulted in many sales that may have been missed if not for her conscientiousness. Carol Anglin came to Cardio Infrared Technologies, Inc. with over 25 years of sales experience which includes selling photography, Tanning equipment and Time Shares. Carol has a strong desire to help people gain a healthier and more natural way of improving their lives. Carol's son Scott died of bone cancer at age 20 which led her to a quest to find other alternative ways to keep the body in a natural healthy state of being.''
Wayne Bailey, President and CEO of Cardio Infrared Technologies, Inc. further commented, ''The preliminary results from the Clinical Trials are very encouraging and have resulted in an expansion of clinical trials to include additional health aspects that were not included in the original clinical trial outline. This expansion is a very exciting development for the future of the Cardio-Cor unit because it will expand the market and improve the demand for the units not only this year but for many years to come. Many shareholders of Cardio Infrared Technologies, Inc. are professional health care providers and they have recognized the benefits of using infrared technology for healing and are eagerly awaiting the final results of the Clinical trials.''
Clinical Trials are expected to be completed in late 3rd quarter.
For more info: http://gnta.realpennies.com
GENTA INCORPORATED (OTCBB: GNTA)
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, visit www.genta.com.
GNTA News:
May 29 - Long-Term Followup in Phase 3 CLL Trial Shows Genasense is Associated with Significantly Increased Survival in All Responders
New Data to be Presented at ASCO Shows Survival Benefit in Complete and Partial Responders Compared with Chemotherapy Alone
Genta Incorporated (OTCBB: GNTA) announced the results of long-term followup from a Phase 3 trial of the Company's lead oncology product, Genasense (oblimersen sodium) Injection, in patients with chronic lymphocytic leukemia (CLL). With 5 years of followup, new data show that patients who achieved either a complete response (CR - the trial's primary endpoint) or a partial response (PR) have also achieved a statistically significant increase in overall survival. The data will be featured in an oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 2, 2008.
In the Phase 3 trial, 241 patients with relapsed or refractory CLL were randomly assigned to receive chemotherapy with fludarabine plus cyclophosphamide (Flu/Cy) with or without Genasense. This study achieved its primary endpoint, which was a statistically significant increase in the proportion of patients who achieved a complete or nodular partial response (CR) with the addition of Genasense to the Flu/Cy regimen. (17% vs. 7%; P=0.025). In addition, the median duration of CR was also significantly longer for patients treated with Genasense (median not reached but estimated to exceed 36 months vs. 22 months).
Previous analyses showed a significant benefit in overall survival accrued to patients who attained CR. Extended followup has shown that all major responses (CR+PR) achieved with Genasense have now been associated with significantly increased overall survival compared with all major responses achieved with chemotherapy alone (median = 56 months vs. 38 months, respectively). At 5 years, 22 of 49 (45%) responders in the Genasense group remain alive compared with 13 of 54 (24%) responders in the chemotherapy-only group.
Moreover, with 5 years of follow-up, 12 of 20 patients (60%) in the Genasense group who achieved CR are alive, 5 of these patients remain in continuous CR without relapse, and 2 additional patients have relapsed but have not required additional therapy. By contrast, only 3 of 8 CR patients in the chemotherapy-only group are alive, all 3 have relapsed, and all 3 have required additional anti-leukemic treatment.
The Company has requested a meeting with the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA) to review this new information.
A scientific report of the initial safety and efficacy findings from this study was recently published (Journal of Clinical Oncology 25:1114, 2007).
ABOUT CHRONIC LYMPHOCYTIC LEUKEMIA
CLL is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions. Patients with CLL typically develop symptoms that may progress over a period of years, ultimately producing a generalized depression of immunity, marked increases in the size of spleen, liver and lymph nodes, and impaired production of other normal blood cells. Eventually, these problems may cause life-threatening complications, such as overwhelming infections and fatal bleeding. More information about CLL can be accessed at the website for the Lymphoma Research Foundation at www.lymphoma.org.
ABOUT GENASENSE
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.
For more info: http://arsc.realpennies.com
AMERICAN SECURITY RESOURCES CORPORATION (OTCBB: ARSC)
ARSC is a holding company actively seeking to acquire companies and technologies that will advance the development of clean energy. ARSC, through its Hydra subsidiary, is developing high volume, mass producible hydrogen fuel cells. Its American Hydrogen subsidiary holds an exclusive worldwide license granted by Ohio University (www.ohio.edu) to commercialize an ammonia-to-hydrogen technology developed by Dr. Gerardine Botte of the Russ College of Engineering at Ohio University. For more information, visit www.americansecurityresources.com.
ARSC News:
May 29 - American Hydrogen Corp. Not In Default; Working on Joint Ventures for Major Developments
Ben Schafer, President of American Hydrogen Corporation, a subsidiary of American Security Resources Corporation (OTCBB: ARSC), stated that, "Contrary to a statement in ARSC's most recent 10-Q, we are NOT in default on our license agreement with Ohio University. "While our sister company Hydra Fuel Cell Corp. was fighting its patent lawsuit we fell behind in our obligations here, but we are working with Ohio to bring them current by the middle of the summer."
Schafer further stated, "We are negotiating several JV projects to commercialize the ACE technology, including the development of a 250 kilowatt ACE unit and several waste to energy projects."
Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html
Sponsored by: http://www.isthemarketopen.com
RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com
No comments:
Post a Comment